MindWalk (HYFT) Q1 2027 earnings summary

Executive summary

• Launched ReefIQ™, a proprietary platform for structuring complex biological data for AI-driven drug discovery and enterprise adoption.

• Active negotiations with multiple large pharmaceutical companies for ReefIQ™ deployments; discussions are broader than previous LensAI agreements.

• Commercial strategy is shifting toward multi-year platform partnerships and recurring revenue, with ~80% of the commercial funnel by value partnership-structured.

• Validated production deployment of OpenFold3 on AMD Instinct MI325X GPUs with AMD and Vultr, supporting platform scale and deployment.

• Internal pipeline is advancing through preclinical development, with experienced leaders added to accelerate IND-enabling work.

Financial highlights

• Q1 FY2027 revenue was CAD 4.115 million, up 21% year-over-year.

• Gross profit was CAD 2.2 million, up 47.1%; gross margin was 58.6%, up from 48.3%.

• Net loss from continuing operations widened to CAD 6.1 million, or CAD 0.13 per share, from CAD 4.1 million, or CAD 0.09 per share.

• Operating expenses were CAD 8.4 million, up 47% year-over-year, primarily from sales and marketing and non-cash stock-based compensation.

• Adjusted EBITDA from continuing operations was CAD (2.466) million.

Outlook and guidance

• Revenue may remain lumpy near term due to milestone-based initial ReefIQ™ agreements; recurring revenue is expected to increase as contracts mature.

• No specific timeline was provided for major ReefIQ™ agreements; negotiations are ongoing with management expressing confidence and visibility.

• The commercial model is designed for multi-year recurring revenue as clients expand platform use; the $30 million facility can support enterprise onboarding and partnerships.